Related Experiment Videos
Paediatric kidney transplantation
J Laine1, H Jalanko, K Rönnholm
1Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland.
Insights
Pediatric kidney transplant recipients face long-term challenges like chronic rejection and drug side effects. Optimizing immunosuppression is key for better graft survival and fewer complications in these young patients.
Area of Science:
- Nephrology
- Pediatric Surgery
- Immunology
Background:
- Renal transplantation is the preferred treatment for end-stage renal disease in children, significantly improving quality of life.
- Despite short-term success, long-term issues such as chronic rejection and drug toxicity persist, limiting allograft survival.
- Current treatment protocols, often adapted from adults, may not fully account for pediatric metabolic differences.
Purpose of the Study:
- To highlight the persistent long-term challenges in pediatric renal transplantation.
- To emphasize the need for individualized immunosuppressive strategies in pediatric recipients.
- To advocate for understanding new immunosuppressive drugs' properties in children for optimal outcomes.
Main Methods:
- Review of current challenges in pediatric renal transplantation.
- Analysis of long-term outcomes and side effects of immunosuppressive therapy.
- Discussion of the need for pediatric-specific therapeutic approaches.
Main Results:
- Allograft half-life has stagnated due to chronic rejection and noncompliance.
- Immunosuppressive drugs pose risks like nephrotoxicity and malignancy, particularly concerning for long-term pediatric use.
- Pediatric recipients may require multiple re-transplantations in adulthood.
Conclusions:
- There is a critical need for improved long-term management strategies in pediatric kidney transplantation.
- Individualized immunosuppression, considering pediatric-specific factors and new drug profiles, is essential.
- Balancing graft survival with minimizing adverse effects is paramount for pediatric renal transplant recipients.
Abstract:
Renal transplantation is the optimal form of renal replacement therapy leading to substantial improvement in the quality of life. It has rapidly become the standard treatment for end-stage renal disease in children. However, despite impressive short-term results significant long-term problems remain unsolved. Because of the lack of effective treatment for chronic rejection and common recipient noncompliance, allograft half-life has not improved significantly during the last decade. A paediatric recipient is likely to need several retransplantations in adulthood. Moreover, the immunosuppressive drugs used today have potentially serious side-effects including nephrotoxicity and de novo malignancy. These are especially relevant for paediatric recipients who will continue to receive therapy for several decades. Most therapeutic protocols used for children are derived from those used for adults. However, the metabolic differences between an adult and a growing and developing paediatric transplant recipient are not always adequately appreciated before these new therapies are initiated. In the near future, we are likely to see new and more efficient drugs become available. It is important that we try to understand their properties in children and use them and our current arsenal on an individual basis aiming at optimal graft survival but also at avoiding unnecessary adverse effects.